EMA committee recommends approval of AstraZeneca's fixed─duration Calquence─based regimens for 1st─line chronic ...
A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated …